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Abstract
The P2Y1 receptor is a member of the P2Y family of nucleotide-activated G protein-coupled
receptors, and it is an important therapeutic target based on its broad tissue distribution and
essential role in platelet aggregation. We have designed a set of highly selective and diverse
pharmacological tools for studying the P2Y1 receptor using a rational approach to ligand design.
Based on the discovery that bisphosphate analogues of the P2Y1 receptor agonist, ADP, are partial
agonists/competitive antagonists of this receptor, an iterative approach was used to develop
competitive antagonists with enhanced affinity and selectivity. Halogen substitutions of the 2-
position of the adenine ring provided increased affinity while an N6 methyl substitution eliminated
partial agonist activity. Furthermore, various replacements of the ribose ring with symmetrically
branched, phosphorylated acyclic structures revealed that the ribose is not necessary for
recognition at the P2Y1 receptor. Finally, replacement of the ribose ring with a five member
methanocarba ring constrained in the Northern conformation conferred dramatic increases in
affinity to both P2Y1 receptor antagonists as well as agonists. These combined structural
modifications have resulted in a series of selective high affinity antagonists of the P2Y1 receptor,
two broadly applicable radioligands, and a high affinity agonist capable of selectively activating
the P2Y1 receptor in human platelets. Complementary receptor modeling and computational
ligand docking have provided a putative structural framework for the drug-receptor interactions. A
similar rational approach is being applied to develop selective ligands for other subtypes of P2Y
receptors.
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INTRODUCTION
The concept that adenine and uridine nucleotides function as extracellular signaling
molecules has expanded markedly in the last decade. At least fifteen nucleotide-activated
cell surface receptors exist in mammals, and remarkably broad and varied physiological
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responses occur downstream of nucleotide receptor activation [1, 2]. The significance of
extracellular nucleotides also is underscored by the ubiquitous distribution of several large
classes of ectoenzymes that catalyze nucleotide breakdown and interconversion [3, 4].
Responses to nucleotides, which occur in essentially all tissues, are mediated by two distinct
families of cell surface receptors. The P2X receptors are a family of seven different (P2X1
through P2X7) ligand-gated ion channel receptors that conduct extracellular cations in
response to ATP [5]. The P2Y receptors (Fig. 1) are a group of eight molecularly defined G
protein-coupled receptors (GPCR) that can be divided into two subfamilies based on relative
sequence similarity and shared downstream signaling mechanisms [6, 7]. The P2Y1 receptor
subfamily consists of the Gq-coupled P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 receptors, and
the P2Y12 receptor subfamily consists of the Gi-coupled P2Y12, P2Y13, and P2Y14
receptors. The cognate agonists of the P2Y receptors include at least 5 different nucleotides
and nucleotide sugars. The P2Y1, P2Y12, and P2Y13 receptors are selectively activated by
ADP, the P2Y2 receptor is activated by both ATP and UTP, the P2Y4 receptor is activated
by UTP, the P2Y6 receptor is activated by UDP, the P2Y11 receptor is activated by ATP,
and the P2Y14 receptor is activated by UDP-glucose (and other nucleotide sugars). The
distribution of these receptors remarkably overlaps in a broad range of cell types and tissues.
Pharmacological resolution of the actions of individual P2Y receptors in these tissues is both
difficult and complex in part due to the existence of ectoenzymes on the cell surface that, for
example, inactivate the cognate agonist for one type of P2Y receptor while producing the
cognate agonist for another [3, 8-13].
Drugs that reliably activate or antagonize a given P2Y receptor subtype would help
surmount the difficulties inherent in the study of these receptors with natural nucleotide
agonists, but such drugs largely have not been available. Therefore, a major goal of the
research of our laboratories has been to generate agonist and antagonist molecules of high
affinity and selectivity for individual P2Y receptors. Our focus to date has been on
development of drugs for the Gq-coupled members of the P2Y receptor family. Structure-
activity studies have led to identification of analogues that exhibit selectivity for the P2Y2,
P2Y4, or P2Y6 receptor [14-17], but the most significant progress has been made in
development of selective high affinity antagonists, agonists, and radioligands for the P2Y1
receptor. This receptor is broadly distributed in the central nervous system and in peripheral
tissues. It plays an indispensable physiological role in ADP-promoted platelet aggregation
and is a drug target of considerable therapeutic interest [18-21]. This review focuses on the
development, identity, and pharmacological properties of P2Y1 receptor-directed molecules.
STRATEGY
Our progress in drug development has relied heavily on: (i) knowledge and experience in
directed medicinal chemistry related to nucleotides, nucleosides, and their analogues; (ii) a
robust inositol lipid cell signaling response in a stable cell line expressing the recombinant
human P2Y1 receptor; (iii) a radioligand binding assay that was developed from studies
applying (i) and (ii) to generate a high affinity radio-labeled antagonist that provides a very
sensitive means to quantify affinities of test drugs with membranes from Sf9 insect cells
expressing recombinant human P2Y1 receptor at high levels; and (iv) an iterative molecular
model of the binding pocket of the P2Y1 receptor developed from the known structure of the
seven transmembrane-spanning receptor rhodopsin. Our approach to drug development has
applied classical molecular pharmacological approaches that do not rely on high throughput
technology. Instead, our philosophy is centered on the view that molecular knowledge of
this particular receptor and its associated cell signaling system, together with the attendant
biochemical assays we have developed, is well-suited for a focused iterative approach that
applies molecular modeling, rational medicinal chemistry, and drug testing with very precise
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and reproducible model systems in multiple rounds of structure-activity analyses. Optimized
research tools for the P2Y1 receptor have evolved from this approach, which is now being




Assays quantifying agonist/antagonist activity of drugs are accomplished by quantification
of [3H]inositol phosphate accumulation in 1321N1 human astrocytoma (P2Y1-1321N1) cells
stably expressing the human P2Y1 receptor [20]. One advantage of the 1321N1 cells is that
they do not express endogenous P2Y receptors. Assays are accomplished in formats using
up to a 96-well plate system. We have applied scintillation proximity assay technology for
quantification of phospholipase C activity [22], although the traditional Dowex ion
exchange chromatography system works equally well for most of our purposes. Briefly,
phosphoinositide pools of P2Y1-1321N1 cells (grown on 12- to 96-well plates) are
metabolically labeled with [3H]inositol (typically 1 μCi/well) overnight, and drugs are tested
the following day during 30 minute incubations in the presence of 10 mM LiCl, which
inhibits inositol phosphate phosphatase activity and enhances the signal resulting from P2Y1
receptor-stimulated phospholipase C activity. Full agonists of the P2Y1 receptor promote
>10-fold stimulation of [3H]inositol phosphate accumulation over basal levels. Newly
synthesized drugs are initially tested at single concentrations (10 μM) alone as well as in the
presence of an approximately EC70 concentration (50 nM) of the full agonist 2MeSADP (4);
see Fig. 2 for drug structures. If agonist activity is revealed in the test drug, then full
concentration-effect curves are generated to obtain an EC50 value relative to that of
2MeSADP (4) and the cognate P2Y1 receptor agonist ADP (1). Representative
concentration-effect curves for two agonists are illustrated in Fig. 3. If antagonist activity is
revealed, then full Schild analyses are performed to determine a KB value and to establish
that antagonist activity is indeed competitive. Briefly, these analyses require the generation
of concentration-effect curves for 2MeSADP (4) alone and for 2MeSADP (4) in the
presence of increasing concentrations of antagonist (Fig. 4). Typically, 2MeSADP (4)
activation curves are generated with 5-6 concentrations of antagonist over at least a 100-fold
range of concentrations. These conditions produce a series of increasingly right-shifted
2MeSADP (4) concentration curves that provide dose-ratios defining how far the activation
curve is shifted to the right by a given concentration of antagonist. As illustrated in Fig. 4
and amplified in the legend of this figure, a simple plot of log (dose ratio-1) vs antagonist
concentration allows regression of a line that provides the pKB on the X-axis. Observation
of a slope of unity in these plots also confirms the competitive nature of the interaction of
the agonist and antagonist molecules with the receptor [23-25].
Radioligand Binding
Prior attempts to quantify P2Y1 receptors using a variety of nucleotide radioligands were
plagued with inconsistent and often very misleading results. Therefore, progress in the study
of this receptor has been impeded by the lack of availability of a generally applicable
radioligand. We describe below our success in developing MRS2279 (14) as a high affinity
antagonist of the P2Y1 receptor. As we have described in detail [26], this molecule was
radiolabeled using [3H]methylamine to high specific radioactivity and used to develop the
first generally successful antagonist radioligand binding assay for P2Y1 receptors. Briefly,
competition curves for newly synthesized drugs (Fig. 5) are generated by incubating a range
of concentrations (10-12 concentrations over a 1000-fold range) of each analogue with a
fixed concentration (5 nM) of [3H]MRS2279 (15) near its Kd and a small amount (5 μg) of
membranes prepared from Sf9 insect cells expressing recombinant human P2Y1 receptor.
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Reactions are terminated by filtration over glass fiber filters, and receptor-bound
radioactivity determined by scintillation spectrometry. Ki values are calculated from IC50
values of the competing drug according to the equation: Ki = IC50/1 + [[3H]MRS2279]/Kd.
Molecular Modeling
A molecular model of the P2Y1 receptor (Fig. 6) was constructed using the electron density
map of bovine rhodopsin as a template [27]. Using molecular dynamics simulations, an
energetically sound conformational hypothesis was generated identifying transmembrane
domains (TMs), extracellular loops (ELs), and a short amino terminus. Various ligands were
docked into the model to establish a putative binding site, and these studies were
complemented with site-directed mutagenesis to confirm the requirement of specific
residues for the coordination of agonists and antagonists in the binding site. A principal
binding domain was established identifying residues necessary for coordinating various
atoms of the nucleotide (Fig. 7). Gln307 and Ser314 of TM7 are in contact with the adenine
ring while the phosphate groups of both polyphosphate agonists and bisphosphate
antagonists reside in a positively charged pocket formed by Arg128 (TM3), Lys280 (TM6),
and Arg310 (TM7). Based on site-directed mutagenesis studies, the physical properties of
these residues appeared to be more important than their absolute conservation, since agonist
activation was restored in S314T and R310K mutant receptors [28]. Supporting the identity
of the proposed binding pocket and the accuracy of the models, a ligand and structure-based
consensus model (LIST-CM) proved capable of predicting quantitatively the potencies of a
novel set of bisphosphate antagonists [29].
In addition to the principal binding domain, two additional binding sites comprised by EL2
and EL3, termed meta-binding sites, were identified and a three-step model for ligand
binding proposed, with association at the meta-binding sites necessarily preceding binding at
the principal site (Fig. 7). In meta-binding site I, Glu209 and Arg287 help coordinate the
ribose ring and α and β phosphates of ATP, respectively. Meta-binding site II exists just
beneath EL2 and shares amino acids Arg128, Lys280, and Gln307 with the principal binding
site. Residues determined to be essential for ligand recognition are likely necessary for the
formation of stable intermediates during the multistep ligand binding process [27].
DEVELOPMENT OF COMPETITIVE ANTAGONISTS OF THE P2Y1
RECEPTOR
Discovery of Adenosine Bisphosphates as Competitive Antagonists of the P2Y1 Receptor
Molecules such as reactive blue-2, suramin, and PPADS were first used as potential
antagonists of P2 receptors. Although small degrees of selectivity were observed with
certain receptors including the P2Y1 receptor [30-32], these drugs largely proved to be at
best only slightly selective antagonists that exhibited only low to moderate potency. The
original breakthrough in identification of P2Y1 receptor antagonists came with our discovery
that adenosine-3′-phosphate-5′-phosphosulfate (A3P5PS, 8) is a partial agonist at the avian
P2Y1 receptor; follow-up Schild analyses illustrated that this molecule behaved as a true
competitive antagonist [25]. We subsequently discovered that the sulfate substitution was
dispensable and that adenosine-3′-phosphate-5′-phosphate, (A3P5P, 7), also was a
competitive antagonist. Moreover, studies with the human P2Y1 receptor stably expressed in
1321N1 human astrocytoma cells also revealed that both A3P5PS (8) and A3P5P (7)
exhibited competitive antagonist activity at the mammalian P2Y1 receptor ortholog [25].
The pKB value for A3P5P (7) at the human P2Y1 receptor was 6.05. The selectivity of these
bisphosphate molecules as P2Y1 receptor antagonists was revealed by demonstration of lack
of antagonist activity at the Gq-linked P2Y2, P2Y4, or P2Y6 receptors or at a Gi-linked P2Y
receptor of C6 glioma cells now known to be the P2Y12 receptor. The availability of these
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P2Y1 receptor selective antagonists played a key role in pharmacological delineation of the
existence of two distinct receptors (the P2Y1 and the P2Y12 receptors) on platelets that
mediate the aggregation response to ADP [33, 34]. Moreover, the discovery of these
bisphosphate analogues was logically followed by synthetic efforts designed to increase the
affinity for P2Y1 receptors, the level of receptor selectivity, and the resistance to degradation
in multiple series of synthetic bisphosphate analogues.
Synthetic Nucleotide Analogues as Competitive Antagonists
A3P5P (7) was utilized as the core molecule for initial synthetic efforts directed toward
obtaining antagonist molecules that exhibited increased affinity for the P2Y1 receptor. Initial
studies utilized turkey erythrocyte membranes as a model system for rapid assessment of
molecules at a Gq/phospholipase C-linked P2Y1 receptor. This system was eventually
replaced with the engineered cell line, i.e. hP2Y1-1321N1 cells, discussed above.
Substitutions on various positions of the adenine ring of adenosine bisphosphates were
explored, followed by modifications and replacement of the ribose ring with various cyclic
and acyclic structures and substitutions of the 3′ and 5′ phosphates with uncharged
functional groups. These studies were complemented with molecular modeling of the
receptor to predict the energy and space determinants governing recognition of the various
nucleotide analogues in the putative receptor binding site.
Substitutions at the 2-position of the adenine ring were well-tolerated at the avian P2Y1
receptor with preference for chloro and methylthio substitutions, which conferred up to 3-
fold increases in antagonist potency while retaining partial agonist activity [35, 36].
Substitutions at the 6- and 8-positions of adenine were largely disadvantageous, resulting in
molecules that interacted poorly with the receptor.
Of particular importance was the finding that addition of a methyl group at the N6 position
eliminated partial agonist activity at the turkey P2Y1 receptor and increased the potency of
adenosine bisphosphates as antagonists [35]. The N6-methyl substitution was sufficient to
eliminate the partial agonist activity of a broad range of modified adenine nucleotide
derivatives, generating a template on which to design purely competitive antagonists. Other
substitutions at this position, including alkyl groups of longer chain length, a benzoyl group,
or chloro or hydroxyl groups resulted in either decreased potency or complete loss of
activity. Modification of the ribose ring indicated that the unphosphorylated hydroxyl group
of A3P5P (7) was not required for recognition at the turkey P2Y1 receptor. The 2′-deoxy
modification also tended to remove any residual agonism of the nucleotide derivatives at the
P2Y1 receptor and eliminated activity at adenosine receptors, thus favoring a selective, pure
antagonist.
MRS2179
The series of structure-activity studies described in the previous section resulted in synthesis
of N6-methyl-2′-deoxyadenosine-3′,5′-bisphosphate (MRS2179, 9). This molecule was the
first highly selective, competitive antagonist of mid-nanomolar affinity for a P2Y receptor,
and has been widely applied in pharmacological studies of the P2Y1 receptor in a variety of
tissues. Schild analysis of the capacity of MRS2179 (9) to inhibit 2MeSATP-promoted
inositol phosphate accumulation in turkey erythrocyte membranes revealed pure competitive
antagonist activity [24]. A pKB of 6.99 was determined. Similar results were obtained with
the corresponding 2′,5′ bisphosphate analogue. The activity of MRS2179 (9) also was
examined at the P2Y1 receptor of human and rat platelets. MRS2179 (9) inhibited ADP-
promoted shape change, aggregation and Ca2+ release with a pKB of 6.55 [38]. Moreover,
MRS2179 (9) exhibited no effect on the ADP-promoted inhibition of adenylyl cyclase.
Thus, MRS2179 (9) does not interact with the ADP-activated P2Y12 receptor of platelets,
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which has led to its wide use as a selective and potent inhibitor of ADP-induced platelet
aggregation occurring via activation of the P2Y1 receptor.
The identification of MRS2179 (9) as a highly selective competitive antagonist and its
subsequent commercial availability made possible the use of this molecule to identify or
exclude a role for P2Y1 receptor function in other tissues and physiological systems. For
example, roles for P2Y1 receptor activity were revealed in astrocyte survival and in
inhibitory neurotransmission in the central and peripheral nervous systems [39, 40].
Acyclic Derivatives and Other Non-Nucleotide P2Y1 Receptor Antagonists
A major goal of our drug development has been to produce high affinity P2Y1 receptor
ligands that do not contain a core nucleotide structure. Such molecules predictably should
not interact with the thousands of nucleotide binding proteins encoded by the mammalian
genome, and also should exhibit reduced susceptibility to metabolism by ectonucleotidases,
which very specifically recognize nucleotides as substrates. Toward this end, several
replacements of the ribose entity were explored. A series of acyclic nucleotide analogues
bearing symmetrically branched phosphorylated aliphatic chains or carbocyclic rings was
produced.
Phosphorylated and symmetrically branched isopentyl, isobutyl, and isopropyl groups
attached at the 9-position of the adenine ring all retained competitive antagonist activity at
the P2Y1 receptor and exhibited no agonist activity [40]. Indeed, the analogue containing an
isobutyl group, MRS2298 (10), exhibited antagonist potency at the turkey P2Y1 receptor
(IC50 = 0.48 μM) similar to that of its N6-methyl bisphosphate precursor, MRS2179 (9).
Replacement of one of the phosphate groups with an uncharged ester greatly decreased
potency at the turkey erythrocyte P2Y1 receptor and in washed human platelets while
replacement of both phosphate groups with uncharged esters greatly decreased potency at
the avian P2Y1 receptor while retaining inhibitory activity in washed human platelets [41,
42]. Interestingly, the uncharged diesters, such as the dipivaloyl derivative MRS2395 (11),
were capable of blocking ADP-promoted inhibition of cAMP accumulation in platelets but
not the Ca2+ increase, suggesting that these compounds were recognized by the P2Y12 but
not the P2Y1 receptor [42]. However, replacement of the bisphosphate groups of MRS2298
(10) with the more stable phosphonates, in MRS2496 (12), resulted in retention of P2Y1
receptor affinity (Ki = 76 nM, in P2Y1 receptor binding assays). Additionally, an analogue
containing a bisphosphorylated alkyl group with a cyclopropyl core attached at the 9-
position of the N6-methlyadenine ring, MRS2290 (13), was recognized by the turkey P2Y1
receptor albeit with lower potency (IC50 = 1.74 μM) than the riboside [43].
Analogues containing several different types of ring structures retained activity at the P2Y1
receptor. For example, six-membered ring anhydrohexitol bisphosphate analogues displayed
micromolar potency. These molecules exhibited agonist action when containing a 6-NH2
substitution while N6-methyl substitution resulted in competitive antagonist action [44]. In
contrast, another set of morpholine ring-substituted analogues were essentially inactive at
the P2Y1 receptor [45]. Collectively, these studies revealed that the ribose ring is not
necessary for recognition by the P2Y1 receptor binding site, and opened up several new
avenues for development of non-nucleotide P2Y1 receptor ligands [43, 45-47].
Conformationally Constrained Nucleotide Analogues as Competitive P2Y1 Receptor
Antagonists
The importance of sugar puckering in adenine nucleotides has been assessed previously, and
for example, conformational preference was illustrated in a series of nucleotide analogues
acting as antiviral agents [48]. Thus, the possibility was considered that phosphorylated
Houston et al. Page 6













carbocyclic rings constrained in either the Northern or the Southern conformation by a fused
cyclopropane ring would prove advantageous in development of selective ligands of the
P2Y1 receptor. In the case of the weak agonist ATP (2), the Northern-constrained derivative
was 200-fold more potent as a P2Y1 receptor agonist than the unconstrained molecule and
250-fold more potent than the Southern-constrained derivative, indicating a substantial role
for sugar puckering in recognition at the P2Y1 receptor [46]. Using the molecular homology
model of the P2Y1 receptor based on the structure of bovine rhodopsin (Figs. 6,7), ATP (2)
and MRS2179 (9) were docked in the putative binding site and found to reside in the
binding pocket preferably in the Northern (N) conformation, which was energetically
favored by 20 kcal/mol over the Southern conformation [45]. These results translated well to
several nucleotide derivatives and enhanced potency was observed for (N)-constrained
agonists and antagonists at the P2Y1 receptor. This conformational preference applied to
some, but not all of the Gq-coupled P2Y receptor subtypes [46], indicating similarities in the
binding pockets of nucleotide receptors, which were later further analyzed through a series
of molecular modeling studies [14, 15, 17, 28].
MRS2279
Our studies with conformationally constrained pseudosugar-containing analogues led to
identification of a non-nucleotide antagonist for the P2Y1 receptor, 2-chloro-N6-methyl-(N)-
methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate (MRS2279, 14) that has proved to be a
widely useful pharmacological agent [23]. MRS2279 (14) exhibited a pKB of 8.10 for the
human P2Y1 receptor. Moroever, it blocked the human platelet P2Y1 receptor and platelet
aggregation with a pKB of 8.05, while exhibiting no effect on ADP-dependent activation of
the platelet P2Y12 receptor. MRS2279 (14) also had no effect on activation of the P2Y2,
P2Y4, P2Y6, or P2Y11 receptors by their cognate agonists.
MRS2500
Substitutions at the 2-position of adenine nucleotides increase ligand affinity for the P2Y1
receptor and P2Y12 receptors [30, 36, 49]. Thus, we determined whether halogen
substitutions of the 2-position in various methanocarba analogues would result in molecules
with increased affinity for the P2Y1 receptor. Indeed, as is illustrated in Fig. 5, a 2-iodo
derivative (MRS2500, 16) exhibited a 10-fold higher affinity than MRS2279 (14) for the
P2Y1 receptor [50]. The sub-nanomolar affinity and non-nucleotide structure of this
molecule provides an important new reagent for the study of P2Y1 receptors both for
pharmacological studies in tissues and animals and for quantification of receptors with a
very high affinity radioligand (see below).
Although MRS2179 (9) and MRS2279 (14) effectively inhibited platelet aggregation
through blockade of P2Y1 receptors in vivo, MRS2500 (16) proved more stable in vivo, and
its much higher affinity make it an attractive candidate for antiplatelet testing. MRS2500
(16) potently inhibited collagen and epinephrine-induced thrombus formation in mice, as
well as thrombus formation in response to laser-induced vascular injury [51]. Additionally,
the combination of MRS2500 (16) and the irreversible P2Y12 antagonist clopidogrel was
more effective than either drug alone in a mouse model of arterial thrombosis, suggesting
benefits of combination antiplatelet therapy targeting P2Y1 and P2Y12 receptors. MRS2500
(16) alone also caused only a modest increase in bleeding time, suggesting advantages of
reversible, competitive P2Y1 receptor antagonists with regard to safety.
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DEVELOPMENT OF RADIOLIGAND BINDING ASSAYS FOR THE P2Y1
RECEPTOR
[3H]MRS2279
The notable advantages contributed by generation of a non-nucleotide high affinity
competitive antagonist of the P2Y1 receptor placed us in position to develop the first
generally applicable antagonist radioligand for this receptor. The presence of a methyl-
substitution at the N6 position in bisphosphate analogues increases P2Y1 receptor affinity
and selectivity while decreasing the propensity of some of these bisphosphate analogs to
exhibit partial agonist activity. We took advantage of this substitution by synthesizing a
precursor molecule that, when reacted with [3H]methylamine, provided [3H]MRS2279 (15)
harboring three tritium atoms in the N6-methyl group and a radioligand with a specific
radioactivity of 89 Ci/mmole. [3H]MRS2279 (15) bound to the human P2Y1 receptor
overexpressed in Sf9 insect cell membranes with a KD of 7.05 nM, and various nucleotide
antagonists inhibited [3H]MRS2279 (15) binding with pharmacological selectivity predicted
from previous studies [26]. [3H]MRS2279 (15) also specifically bound to the endogenous
P2Y1 receptor of rat brain and human platelets with affinity and selectivity similar to that
observed for the recombinant human receptor. Due to extensive metabolism of nucleotide
agonists, agonist affinities were not determined in these membrane preparations. However,
[3H]MRS2279 (15) was utilized to quantify active receptor during purification to
homogeneity of the human P2Y1 receptor after its overexpression from a recombinant
baculovirus in Sf9 insect cells [52]. Moreover, the availability of purified P2Y1 receptor
allowed us to determine for the first time the affinities of agonists for the P2Y1 receptor.
These include 2MeSADP (4), 2MeSATP (5), ADP (1), ATP (2), and ADPβS (3), which
exhibited Ki values of 0.1 μM, 1.9 μM, 0.9 μM, 18 μM, and 2.4 μM, respectively. The
availability of [3H]MRS2279 (15) also provided us with the first useful radioligand binding
assay suitable for screening P2Y1 receptor ligands (Fig. 5). This binding assay complements
previous and subsequent SAR and molecular modeling studies and has provided us with a
very reliable and rapidly accomplished means of assessing newly synthesized nucleotide
analogues.
[32P]MRS2500
Our synthesis of MRS2500 (16) provided a non-nucleotide antagonist with an affinity of 1
nM or less. Moreover, the presence of an iodine in the 2-position of MRS2500 (16)
suggested the possibility of generation of a high specific radioactivity radioligand for the
P2Y1 receptor. Introduction of trimethyltin at the 2-position allowed introduction of 125I
through a reaction catalyzed by chloramine T. Unfortunately, the procedure to obtain
[125I]MRS2500 requires multiple steps, and reliable production of high quantities of
radiolabeled antagonist proved impractical. As such, we sought other means to label
MRS2500 (16) to high specific radioactivity and discovered that a precursor 3′-
monophosphate molecule was a substrate for phosphorylation catalyzed by polynucleotide
kinase. Thus, 32P could be introduced into the 5′-position of the precursor to yield 32P-
labeled MRS2500 in a single step from a reaction that included [γ32P]ATP, the precursor,
and polynucleotide kinase [53]. Thus, we have produced a means for the routine, facile
production of high μCi amounts of [32P]MRS2500 (17) with a theoretical specific activity of
approximately 9120 Ci/mmol. The ease of synthesis of this radioligand obviates potential
problems introduced by rapid radioactive decay of the short half life radioisotope, 32P.
[32P]MRS2500 (17) binds to the recombinant human P2Y1 receptor with a KD of
approximately 1 nM [52]. Moreover, the extremely low concentration of protein (< 1 μg)
needed in typical binding assays with membranes from P2Y1 receptor-expressing Sf9 cells
has allowed us to determine agonist affinities for the first time for the P2Y1 receptor in its
membrane environment. These values are very close to those listed above for the purified
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P2Y1 receptor determined in binding assays with [3H]MRS2279 (15). [32P]MRS2500 (17)
has proved very useful for quantification of P2Y1 receptors in a variety of native tissues. A
binding assay was established measuring relative distribution of P2Y1 receptors in adult rat
organs and brain regions, representing the first determination of the distribution of
functional binding sites. Interestingly, P2Y1 receptors were most densely expressed in the
lung followed by near equal expression in the brain and the liver. Among brain regions,
functional receptor binding sites varied by approximately 6-fold with the highest expression
observed in cerebellum and the lowest in cortex [53]. Because P2Y1 receptors are expressed
on astrocytes, glia and neurons, cellular localization by receptor autoradiography is an
important future application of [32P]MRS2500 (17). Additionally, a binding assay for
[32P]MRS2500 (17) has been established in human platelets. Current work is aimed at using
[32P]MRS2500 (17) to study agonist-promoted regulation of P2Y1 receptor surface
expression in native tissues including platelets and cell lines expressing native and
recombinant receptors.
Development of a P2Y1 Receptor-Selective Agonist
Our observation that the affinity of P2Y1 receptor selective antagonists was enhanced by
replacing the ribose moiety with a constrained carbocyclic ring [45] suggested that such
modifications might enhance affinity and selectivity in agonist molecules. Therefore,
various methanocarba analogues were synthesized, and N-methanocarbo-ATP was found to
be greater than 100-fold more potent than ATP (2) or S-methanocarba-ATP as an agonist at
the P2Y1 receptor [46]. Moreover, combination of the ring-constrained (N)-methanocarba
modification with other functionalities resulted in identification of a remarkably potent P2Y1
receptor agonist [47]. Thus, (N)-methanocarba-2-methylthio-ADP (MRS2365, 6) displayed
a potency (EC50 = 0.4 nM) at the human P2Y1 receptor that was 20-fold greater than the
corresponding riboside 5′-diphosphate (Fig. 3). The fact that ADP (1) is the cognate agonist
for three different P2Y receptors, the P2Y1, P2Y12, and P2Y13 receptors, led us to determine
whether MRS2365 (6) exhibited selectivity among these receptors. Indeed, the (N)-
methanocarba moiety is specifically favored at the P2Y1 receptor, since MRS2365 (6)
proved to be neither an agonist nor antagonist at the P2Y12 or P2Y13 receptors [54]. This
development of a high affinity, highly selective P2Y1 receptor agonist has provided an
important advance for studying platelet function. Thus, the platelet P2Y1 receptor can be
selectively activated without necessitating concomitant blockade of the P2Y12 receptor with
an antagonist of that receptor [54], and therefore, studies of the function and regulation of
the platelet P2Y1 receptor can be accomplished under conditions in which no P2Y12
receptor-directed drugs are present [55]. These studies are ongoing and should lead to better
understanding of the interplay of the P2Y1 receptor and the P2Y12 receptor in platelet
function.
CONCLUDING REMARKS
We have designed a set of selective and versatile ligand tools for studying the P2Y1
receptor. Thus, both high affinity agonists and antagonists have been crafted using a rational
approach to ligand design that derived from the native ligands of the P2Y1 receptor. An
iterative approach led to enhancement of affinity and selectivity and optionally to the
engineered loss of efficacy (while retaining affinity) to arrive at ligand structures having
targeted pharmacological properties. Receptor modeling and computational ligand docking
have supported this effort and provided a putative structural framework for the drug-receptor
interactions. By substituting the ribose moiety with either less rigid or more sterically-
constrained bicyclic ring systems we have optimized the pharmacological profiles. The
achievement of nanomolar affinity at the P2Y1 receptor has enabled the preparation of
radioligands that can provide broad library screening to discover more novel and chemically
Houston et al. Page 9













diverse ligand structures. This approach is now being applied to the rational design of drug
probes for other subtypes of P2Y receptors.
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Mammalian P2Y receptors. The eight molecularly and functionally identified mammalian
P2Y receptors are listed with their cognate agonists and the heterotrimeric G protein Gα-
subunits and effector enzymes most clearly associated with their signaling function. PLC,
phospholipase C; AC, adenylyl cyclase. (+), increase in activity; (−) decrease in activity.
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Agonists and antagonists of the P2Y1 receptor.
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Activation of the P2Y1 receptor by two analogues of ADP. Concentration effect curves for
P2Y1 receptor-mediated activation of phospholipase C were determined for 2MeSADP and
(N)-methanocarba-2MeSADP ((N)-mc-2MeSADP; MRS2365). This figure is from Ravi et
al. [46] and reprinted with permission.
Houston et al. Page 15














Schild analysis of ligand interaction with the P2Y1 receptor. Left Panel, Phospholipase C
activity was measured in the indicated concentrations of the agonist 2MeSADP in the
absence or presence of increasing concentrations (0 (●), 0.03 (■), 0.1 (▲), 0.3 (◆), 1 (○), 3
(□), 10 (Δ), and 30 (◇) μM) of the antagonist MRS2279. Right Panel, A Schild plot was
generated from the data illustrated in A. A dose ratio for each concentration of antagonist
was determined by dividing the concentration of agonist necessary to produce 50% of
maximal effect in the presence of that concentration of antagonist by the concentration of
agonist necessary to produce 50% of maximal effect in the absence of antagonist. Log (dose
ratio-1) was plotted vs concentration of antagonist, and the intercept on the X axis is equal to
the pKB of the antagonist. This figure is from Boyer et al. [23] and reprinted with
permission.
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Inhibition of [3H]MRS2279 binding by P2Y1 receptor ligands. A series of 2-substituted
analogues of MRS2279 were tested as potential high affinity ligands for the P2Y1 receptor
using [3H]MRS2279 as a radioligand and membranes isolated from Sf9 insect cells
expressing recombinant human P2Y1 receptor at high levels. The most potent inhibitor in
this series was MRS2500, whose structure is illustrated in Fig. 2. Various 2-substituted
analogues of MRS2500 are included: 2-fluoro (MRS2520), 2-bromo (MRS2519), and 2-
methylthio (MRS2521). This figure is modified from Kim et al. [50] and reprinted with
permission.
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Molecular model of the human P2Y1 receptor complexed with the antagonist MRS2179 in
space filling representation. Nucleotide agonists and antagonists bind within the upper
portion of the helical bundle, with the phosphate group coordinated by three cationic
residues and the base in contact with residues from TM7. The ribbon representation of the
receptor backbone is depicted with the colors of the rainbow going from the N-terminus to
the C-terminus (TM1: orange; TM2: yellow; TM3: green; TM4: green/blue; TM5: cyan;
TM6: blue; TM7: violet).
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Schematic representation of the putative interaction of MRS2179 with the P2Y1 receptor.
The phosphate moieties are coordinated by a number of basic residues located in TM3,
TM6, and TM7. The nucleobase establishes contacts with residues located in TM1 (Tyr58),
TM3 (Phe131), and TM7 (Gln307 and Ser314). The picture has been generated with the
ligand interaction application of MOE and uses the following annotations: hydrogen bonds
are represented with green arrows; residues highly exposed to the ligand are denoted with a
blue half moon; ligand atoms highly exposed to the receptor are represented denoted with a
blue shadow; polar residues are colored in pink; greasy residues are colored in green; basic
residues are marked with a blue circle.
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